| |
| HEALTHCARE |
Sudanese Doctor Honors at Nigerian Tuberculosis Conference
July 22, 2019
Khartoum, July 21 (SUNA) - In the presence of more than 2000 physicians, The Sudanese Dr. Othman AL Tayeb Othman was honored last Thursday during a Nigerian National Tuberculosis Conference held in Abuja. He was honored for his considerable efforts for treating and countering, TB Resisting Drugs in Nigeria. Dr. Othman told SUNA he has obtained a number of certificates"...
Sudanese Physician Honored in Abuja
July 22, 2019
Khartoum, July 21 (SUNA) - In the presence of more than 2,000 doctors, Dr. Osman al-Tayib Osman was honored at the Nigerian National Tuberculosis Conference Thursday in Abuja as a result of his efforts in the fight against the treatment- resistant tuberculosis in Nigeria. Dr. Osman said, in statement to SUNA, that he received a number of ertificates of appreciation throughout his career, but the honor he received in Nigeria is a proud to him because it came as the result of the great role he played in the establishment and"...
U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)
July 22, 2019
The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans. There is particular urgency at this time as new antennas will be densely located"...
Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
July 22, 2019
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab as maintenance therapy in adult patients with moderately to severely active Crohns disease (CD) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) therapy at weeks 0 and 2.1 In evaluating the primary endpoint of the trial, a statistically significant proportion of patients receiving vedolizumab SC achieved clinical remission** at week 52 compared to placebo. Patients received vedolizumab SC beginning at week 6 and every 2 weeks up to week 50.1 Adverse events were consistent with the known safety profile of vedolizumab IV, and no new signals were identified. “Meeting......
No fee, no blood donation
July 20, 2019
A blood donor in Juba says nurses at the state-run hospital have refused to draw his blood to save his ailing sister unless he pays some amount of money first. Awan Achiek took her sister to the Juba Teaching Hospital this morning. A doctor diagnosed the unnamed patient with insufficient blood and recommended blood transfusion. However, Achiek says the nurses are demanding 1,500 pounds before drawing blood from his body. “They could not tell us the reason why they are demanding for this money,” he told Eye Radio. “Very unfortunately, I don’t have that money. They told me ‘if you don’t have money, then we are not going to do anything’. This is the system…in the hospital.” He told Eye Radio that he had to leave her sister, whom she says in in “critical condition”, to look for money. Authorities at the Juba Teaching Hospital......
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
July 20, 2019
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral"...
Moonlight: Al-Basar Charity Foundation Contributes more in Eye Treatment
July 18, 2019
Al-Basar Charity Foundation is a one of the institutions specialized in ophthalmology that offers its charity services for all people all over the world. Its vision says that all people are the same no difference between them. Who, he follows its charity activities he will know that the Foundation is playing a crucial role in ophthalmology domain.
The foundation was founded in Saudi Arabia Kingdom in 1989 to support efforts to combat blindness in the world. It provides its activities through free camps and hospitals"...
AHF to WHO: Ebola Response, Too Little, Too Late!
July 18, 2019
The World Health Organization (WHO) has finally declared a Public Health Emergency of International Concern (PHEIC) in the Democratic Republic of the Congo on July 17 as a long overdue acknowledgement that the current Ebola outbreak remains uncontained and still poses a significant threat to global health"...
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
July 18, 2019
Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months. Both companies will initially focus"...
Ebola preparedness plan gets $4m
July 16, 2019
Health partners have raised $4 million in an attempt to keep Ebola out of South Sudan, according to Dr. Richard Lako – the director general at the ministry of health. Last month, the ministry appealed to donors for funds to implement its updated 6-month Ebola preparedness plan aimed at preventing spread of the virus from the neighboring countries and to adequately"...
|
|
|
|
|